Renalytix to Present at the 2021 Wells Fargo Virtual Healthcare Conference
Renalytix, trading under the ticker RNLX, announced its participation in the 2021 Wells Fargo Virtual Healthcare Conference scheduled for September 10 at 2:40 p.m. EDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Renalytix, trading under the ticker RNLX, announced its participation in the 2021 Wells Fargo Virtual Healthcare Conference scheduled for September 10 at 2:40 p.m. EDT. This event will feature a fireside chat with the company’s management, accessible via a live and archived webcast on their website. Renalytix is a leader in bioprognosis for kidney health and has developed the KidneyIntelX™ technology, recognized for its potential in chronic kidney disease diagnostics. For more details, visit renalytix.com.
Details
News Market Reaction – RNLX
The recorded move for RNLX in the trading session of this news was -0.93%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and SALT LAKE CITY, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the company will be presenting at the upcoming 2021 Wells Fargo Virtual Healthcare Conference.
Renalytix’s management is scheduled to participate in a fireside chat Friday, September 10 at 2:40 p.m. EDT. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at investors.renalytix.com.
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) Renalytix is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that successfully enables early-stage chronic kidney disease, progression risk assessment. The Company’s lead product is KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.
UK Investor Contact:
| Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com | |
| Paul McManus / Lianne Cawthorne | Mob: 07980 541 893 / 07584 391 303 | |
US Investor Contact:
| CapComm Partners | investors@renalytix.com | |
| Peter DeNardo | 415-389-6400 | |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.